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During the papillomavirus replication cycle, the L2 minor capsid protein enters 
the nucleus in the initial phase after uncoating of the incoming virions and in the 
productive phase when L2 together with L1 major capsid protein mediate the 
encapsidation of the newly replicated viral genome.  L2 proteins of both high risk HPV16 
L2 and low risk HPV11 L2 have two nuclear localization signals (NLSs): one at the N-
terminus (nNLS) and one at the C terminus (cNLS).  The purpose of these experiments is 
to determine the minimal mutations necessary to inhibit the function of the NLSs.  In this 
study, subcellular localization of enhanced green fluorescent protein (EGFP) fusions with 
full length L2 and L2 mutants lacking either the cNLS (EGFP-L2∆C), nNLS (EGFP-
L2∆N), or both NLSs (EGFP-L2∆N∆C) was analyzed in HeLa cell transfection assays.  
Full length HPV16 L2 and HPV11 L2 proteins localize to the nucleus.  For both HPV16 
and 11 L2, each NLS could independently mediate nuclear import in vivo.  EGFP fusions 
were also made with mutated nNLS (EGFP-L2∆CSbN) or mutated cNLS (EGFP-
L2∆NSbC).  Transfected HeLa cells were examined by fluorescence microscopy and 
quantitative studies were done.  In both HPV16 and 11 L2 proteins, mutation of basic 
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Human papillomaviruses (HPVs) have already been identified in 120 different 
types, infecting either epithelial cells of the skin or of the anogenital and oropharyngeal 
mucosa.  In the United States, HPV accounts for more infection than all other sexually 
transmitted diseases combined.  HPV infection has been linked to the etiology of 
numerous types of cancer, most significantly to cervical cancer as well as a large 
proportion of anal, perianal, vulvar, penal, and oropharyngeal cancers.  HPV types are 
classified as either high-risk or low-risk according to their detection in malignant lesions 
or genital warts (condylomata acuminate), respectively.  HPV high-risk types 16, 18, 31, 
33, 39, 45, 52, 58, and 69 and HPV low-risk types 6 and 11 occur with the greatest 
frequency (zur Hausen et al., 2000).  Infection by high-risk strains of HPV accounts for 
approximately 95% of cervical cancer, the second most common and second leading 
cause of cancer death among women worldwide (Bosch et al., 1995).  Among these high-
risk HPV types found in cervical cancer, HPV16 is the most common (50%), with 
HPV18 (15%), HPV45 (8%), and HPV31 (5%) in succession (Bosch et al., 1995).   
Linkage of HPV infection with cervical cancer has been established upon multiple 
grounds.  Strikingly, HPV has been detected in cervical cancer biopsies in 93% of 
samples (Bosch et al., 1995).  Expression of viral oncogenes in tumor material has also 
been detected.  Specifically, oncogenes E6 and E7 have demonstrated transforming 
properties and are required for maintenance of the malignant phenotype in cervical 
carcinoma cell lines.  Further, viral oncoproteins have been shown to interact with 
growth-regulating host-cell proteins.  Epidemiologic studies have also implicated HPV 
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infection as the major risk factor for etiology of cervical cancer (zur Hausen et al., 2000).  
With this mounted evidence, the sexually transmitted HPV has been determined to be the 
central etiologic factor in cervical cancer, with notable homogeneity among countries 
worldwide (Bosch et al., 1995).   
By virtue of their physical properties, human papillomaviruses have been 
classified as a taxonomic group known as Papillomaviridae.  Both low-risk and high-risk 
types of HPV are specifically classified as Alpha-papillomaviridae (de Villiers et al., 
2004).  Electron microscopy of negatively-stained HPV virions has determined them to 
be 55 nm in diameter.  Electron microscopy has also revealed a composition of 72 
capsomeres arranged on a T=7 icosahedral surface lattice with a dextro (right-handed) 
skew (Finch et al., 1967).  Within these nonenveloped capsids is contained a single 
molecule of 8-kb double-stranded circular DNA (Galloway et al., 1989).  The viral 
genome encodes the HPV structural proteins, containing two large open reading frames 
(ORFs), L1 and L2, which are well conserved among all members of the family 
Papillomaviridae (de Villiers et al., 2004).  The primary product of the L1 ORF is the 
major structural protein, with a molecular weight of 57K in HPV1 (Doorbar et al., 1987).  
Each of the 72 individual capsomeres making up the virion is a pentamer of the L1 major 
capsid protein (Baker et al., 1991).  The product of the L2 ORF is the minor structural 
protein, with a molecular weight of 78K in HPV1 (Doorbar et al., 1987).  Additionally, 
the viral genome contains open reading frames (ORFs) for three oncoproteins (E5, E6 
and E7) and two regulatory proteins (E1 and E2) (de Villiers et al., 2004). 
While the organization and number of L1 major capsid proteins present in the 
HPV virion has largely been elucidated, similar data for the L2 minor capsid proteins 
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remains unclear, especially for those of genital HPVs (Buck et al., 2008).  The tight 
coupling of HPV propagation to the differentiation of the host epithelial cells, and 
simultaneous difficulty in creating a stratified model, has significantly impeded in vivo 
study of virion assembly (Doorbar et al., 2005; Hagensee et al., 1993).  In vitro, capsids 
have been shown to self assemble into icosahedral 55 nm particles even when containing 
L1 alone.  However, these capsids were considerably fewer and more variable in 
morphology than those containing both L1 and L2 (Hagensee et al., 1993).  Current 
literature conflicts over the estimated number of L2 molecules per capsid, ranging from 
12 to 36 to recent estimates of up to 72 L2 binding sites in an assembled virion (Roden et 
al., 1996; Kirnbauer et al., 1993; Buck et al., 2008).  L2 has been proposed to interact in 
the capsid hollow with the L1 capsomers at an L2-specific density button beneath each 
unit (Buck et al., 2008).   
 
Human Papillomavirus Life Cycle 
The life cycle of HPV is tightly linked to the differentiation of the host epithelial 
cell.  For initial infection to be achieved, infectious particles must reach the cells of the 
undifferentiated basal epithelial layer, often through a break in the stratified epithelium.  
Upon recognition by a cell surface receptor, endocytosis of the virus occurs through 
clathrin coated vesicles.  The virus is subsequently uncoated and viral DNA is transported 
into the nucleus.   In the basal layer, the nonproductive stage occurs via selective 
expression of the early genes E1 and E2.  In this infective state, the virus utilizes the host 
DNA replication machinery to synthesize its own DNA as a low-copy-number episome.    
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The productive stage occurs as the basal cells proliferate and migrate into upper 
layers of stratified squamous epithelia.  While uninfected basal cells reach terminal 
differentiation shortly after migrating to suprabasal cell layers, those expressing the E6 
and E7 oncoproteins experience a loss of cell cycle progression restraint and do not 
undergo normal terminal differentiation.  E6 and E7 stimulate cell cycle progression as 
they associate with cell cycle regulators.  In the mid or upper epithelial layers, expression 
of all viral early gene products occurs and the viral genome is amplified to a high-copy-
number.   
Once viral genome amplification is complete in the upper layer, the structural 
proteins L1 and L2 are expressed.  The L2 minor capsid protein is expressed before the 
major capsid protein, L1.  L1 and L2 proteins must be imported into the nucleus, where 
they form the icosahedral shell and encapsidate the newly replicated viral DNA to 
complete assembly of the virus.  Virions are eventually released with the shedding of the 
upper layer epithelium and must then survive extra-cellularly until re-infection (Doorbar 
et al., 2004).  
 
L2 Minor Capsid Protein 
While the role of L2 in the HPV life cycle has yet to be completely clarified, 
certain studies have shed light upon the functions of the minor capsid protein.  
Organotypic raft culture studies have shown that L2 participates in at least two steps in 
the life cycle of high risk strain HPV31.  First, L2 deficient HPV31 virions showed a 10-
fold reduction in the amount of encapsidated viral DNA, revealing the critical role L2 
plays in the encapsidation of the viral genome.  Second, those virions lacking L2 also 
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exhibited over a 100-fold reduction in infectivity, lending to L2’s involvement in virion 
assembly and infectivity (Holmgren et al., 2005).   
L2’s role in encapsidating the viral genome may be due to its known association 
with the early protein E2.  It has previously been demonstrated that L2 localizes to 
punctuate nuclear regions known as promyelocytic leukemia (PML) oncogenic domains 
(PODs), or nuclear domains 10 (ND10).  When coexpressed with either L1 or E2, L2 
colocalizes and shifts their locality to the PODs as well (Day et al., 1998).  This 
colocalization of L2 with E2, a facilitator of viral DNA replication, may indicate L2’s 
ability to modulate its function in the productive phase of the viral life cycle (Doorbar et 
al., 2004; Heino et al., 2000).  L2 has more specifically been shown to bind to E2TA, a 
transcriptional transactivator, and relocalize it to these nuclear subdomains.  In binding to 
E2TA, L2 inhibits its function as a transcriptional transactivator but does not disrupt its 
replication function.  L2 also relocalizes E2TR, a transcriptional repressor, to the PODs 
(Heino et al., 2000).  It has been suggested that the PODs to which L2 and its associated 
proteins localize may play a positive role in viral replication (Day et al., 1998).  L2 may 
be recruiting the viral genome to the site of virion assembly, as E2 binds specifically to 
the viral genome (Holmgren et al., 2005; Androphy et al., 1987).  Alternatively, the 
PODs may play a role in cellular antiviral defense, as viral infection disrupts PODs (Ahn 
et al., 1998).   
One essential role of L2 in the infectivity of the virus has been connected to its 
membrane-penetrating activity.  A C-terminal 23-amino-acid peptide from the L2 protein 
was identified as essential for transit of the viral DNA across the endosomal membrane 
during infection.  Though L2 is not required for initial uptake, it is required for egress of 
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the viral genomes from the endocytic compartment after viral uncoating (Kamper et al., 
2006).  Further, a cell-surface binding motif in HPV16 L2, which is conserved in BPV1 
L2, binds to HeLa cell receptors and facilitates infection.  This binding motif is thought 
to function in the infectious process after initial surface binding (Yang et al., 2003).     
L2 minor capsid protein also has the ability to both bind DNA nonspecifically and 
may translocate the viral genome to the nucleus.  In bovine papillomavirus type 1 
(BPV1), L2 functions as an adapter between viral DNA via its nuclear localization signal 
(NLS) at the C terminus (cNLS) and the Kaps involved in nuclear import via its NLS at 
the N terminus (nNLS), thus facilitating nuclear import of the DNA during infection (Fay 
et al., 2004).  Self-assembling virus-like particles (VLPs) containing only L1 of BPV1 
have been found to be noninfectious.  Contrarily, when L1 and L2 are coexpressed, viral 
DNA is detected in the VLPs, indicating that genome encapsidation requires the presence 
of L2.  These results were found in both BPV1 and HPV16 (Roden et al., 1996).   
 
Nuclear Localization Signals 
The L2 minor capsid protein must enter the nucleus twice during viral infection, 
both during the initial phase after virion uncoating and the productive phase of new viral 
DNA encapsidation (Doorbar et al., 2004).  HPV1 L2 localizes to the nucleus when 
expressed alone, signifying that the protein itself contains sequences which direct nuclear 
localization (Hagensee et al., 1993).  It has been determined that nuclear localization of 
both HPV11 L2 and HPV16 L2 is achieved through pathways mediated by two such 
nuclear localization signals (NLSs), one in the N terminus (nNLS) and one in the C 
terminus (cNLS) (Bordeaux et al., 2006; Darshan et al., 2004).  These classical NLSs are 
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composed of basic amino acids, often arginine and lysine, and can each independently 
mediate nuclear import (Moroianu et al., 1999).  Studies on HPV18 L2 have shown this 
high-risk type to also contain an nNLS and cNLS, each of which is capable of 
independently mediating nuclear import (Klucevsek et al, 2006).  An NLS in the middle 
region (mNLS) of HPV16 L2 has previously been proposed, although unsuccessful in in 
vitro import assays at achieving nuclear localization (Darshan et al., 2004).  The NLSs of 
HPV11 L2, HPV16 L2, and HPV18 L2 also appear to be DNA binding sites, with 
binding occurring without nucleotide sequence specificity (Bordeaux et al., 2006; 
Klucevsek et al., 2006).  
 
Nuclear Import Pathways 
In order for macromolecules to enter the nucleus, they must undergo mediated 
transport through the nuclear pore complex (NPC) by soluble transport receptors.  
Nuclear localization signals (NLSs) located on the macromolecules allow recognition, 
either directly or indirectly, by the transport receptors which shuttle between the 
cytoplasm and the nucleus.  Specifically, these NLSs are recognized by import receptors 
of the karyopherin β (Kap β) (importin) family.  The general nuclear import pathway 
consists of the NLS-protein cargo bound directly, or indirectly via an adapter, by an 
import receptor in the cytoplasm.  This complex is then transported through the NPC, the 
cargo is released in the nucleus, and the receptors and adaptors are exported back to the 
cytoplasm.  Directionality of the Kap β import pathways is partially defined by a 
concentration gradient of RanGTP across the NPC.  Distribution of RCCI, the nucleotide 
exchange factor of Ran, inside the nucleus maintains high levels of nuclear RanGTP.  
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Oppositely, RanGAP, a GTPase-activating protein, and RanBP1, a Ran-binding protein, 
are mainly cytoplasmic and thus maintain low levels of RanGTP in the cytoplasm 
(Moroianu et al., 1999). 
The classical import pathway is for proteins containing classic NLSs.  In this 
specific pathway, the NLS-protein cargo requires the involvement of an adaptor, importin 
α, to bind to the import receptor (Moroianu et al., 1999).  Importin α associates both with 
the classical NLS of the cargo and with the importin β binding domain (IBB) of Kap β 
(Fried et al., 2003).  Thus, the NLS-protein/importin α (Kap α)/importin β (Kap β) 
trimeric complex is translocated into the nucleus via interaction of Kap β with 
cytoplasmic nucleoporins of the nuclear pore complex (NPC).  Affinity of the import 
receptors with the NLS-protein cargo is dictated by the concentration gradient of 
RanGTP.  A low concentration of RanGTP in the cytoplasm allows the formation of a 
stable cargo/receptor complex (Moroianu et al., 1999).  A high level of RanGTP in the 
nucleus, however, leads to release of the cargo.  Nuclear RanGTP binds to Kap 
β/importin β to cause dissociation of Kap β from the importin α/cargo complex.  Importin 
α’s IBB, without importin β binding, then causes release of the NLS-protein cargo from 
importin α through autoinhibition.  Finally, Kap β and Kap α are separately exported back 
into the cytoplasm to be reused (Fried et al., 2003).       
The interaction of various import receptors and adapter/receptor heterodimers 
with the L2 minor capsid protein of multiple HPV types has been analyzed.  Specifically, 
HPV11 L2 interacts with Kap β1, Kap β2, and Kap β3 and complexes with the Kap α2β1 
heterodimer (Bordeaux et al., 2006).  HPV16 L2 interacts with Kap β2 and Kap β3 as well 
as the Kap α2β1 heterodimer (Darshan et al., 2004).  Finally, HPV 18L2 interacts with the 
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Kap α2 adaptor, Kap β2, and Kap β3 and also complexes with the Kap α2β1 heterodimer 
(Klucevsek et al., 2006).   
 
Research on Nuclear Localization of L2 Minor Capsid Proteins  
Both HPV11 L2 and HPV16 L2 have been analyzed in vivo and in vitro for 
nuclear localization.  The nNLS and cNLS of L2 proteins of both HPV types 11 and 16 
have been shown to be capable of independently mediating nuclear import of L2.  
However, deletion of both NLSs results in mostly cytoplasmic localization (Bordeaux et 
al., 2006; Darshan et al., 2004).  Research on the mNLS of HPV6b L2 has suggested a 
role in nuclear retention (Sun et al., 1995).  Consequently, the proposed mNLS in HPV16 
L2 may have a similar role (Darshan et al., 2004).   
Given the previous research on the location and independent functioning of the 
NLSs of HPV11 L2 and HPV16 L2, further mutation-function analysis in vivo has been 
conducted.  Single NLS deletions in HPV11 L2 have supported the findings that the 
nNLS and cNLS function independently.  In vivo transfection studies of single NLS 
deletions of HPV16 L2 have provided corroborating evidence with previous studies in 
vitro that its nNLS and cNLS function independently.  Further, while the deletion of both 
the nNLS and cNLS in HPV11 L2 has resulted in mostly cytoplasmic localization, 
HPV16 L2 still retains some nuclear localization.  Thus, the mNLS previously suggested 
in HPV16 L2 may be weakly functional in vivo.  Novel analysis of L2 localization with 
deletion of one NLS and mutation of basic residues in the second NLS has shown a 
complex phenotype in both HPV11 L2 and HPV16 L2.  However, quantitation has shown 
a definite decrease in nuclear localization of these L2 mutants.  Further analysis of L2 
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mutants will then lead to the determination of the minimal mutation necessary to inhibit 
function of the NLSs.  Such L2 mutants will prove vital in analyzing the role of the L2 
protein in nuclear import of viral DNA.   
 
Materials and Methods 
Cell Culture 
 The ATCC HeLa cell line was cultured in Dulbeccos Modified Eagle medium 
(DMEM+) and supplemented with 5% fetal bovine serum (FBS) and Penstrep.  The cells 
were maintained in culture at 37 degrees C and 5 percent CO2. 
 
Preparation of HPV16 and HPV11 EGFP-L2 and mutant EGFP-L2 plasmids 
PCR was used with the pProEX HTb plasmids containing the wild-type HPV16 
and HPV11 L2 and L2∆N, L2∆C, and L2∆N∆C mutants with sequence specific 
oligonucleotides incorporating an EcoRI restriction site to the 5’ end of the sequence and 
a BamHI restriction site to the 3’ end of the sequence. The PCR products were extracted 
from a 0.7% agarose gel using the QIAquick Gel Extraction Kit and double digested with 
EcoRI and BamHI. The pEGFP-C1 vector (EGFP = enhanced green fluorescence protein) 
with a kanamycin resistance gene (Clontech) was also double digested with the restriction 
enzymes EcoRI and BamHI, run on an agarose gel and the linerarized vector was 
extracted in the same manner. The double digested vector and L2 insert were ethanol 
precipitated with a 1:3 vector:insert, 3 M ammonium acetate in a 1:10 of DNA volume 
and 2.5x the total volume of 95% EtOH (-20ºC) and incubated overnight at -20ºC, then 
centrifuged for 30 min (13,000 RPM, 4ºC), supernatant was removed, 200 µl of 70% 
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EtOH (4ºC) was added and centrifuged for 30 min, supernatant removed and DNA was 
air dried at R.T. for 10 min. The insert and vector were resuspended in 15 µl DNase free 
distilled water, 4 µl Ligate-IT 5x buffer, 1 µl Ligase (USB), and ligated for 5 min at R.T. 
on rotator. The HPV16 and HPV11 EGFP-L2, EGFP-L2∆N, EGFP-L2∆C, and EGFP-
L2∆N∆C constructs were transformed into XL1 blue bacteria and confirmed by 
automated sequence analysis (MGH DNA Sequencing Department). 
*Procedure and preparation courtesy of Jennifer Bordeaux  
 
Transfection Assay 
HeLa cells were plated on poly-L lysine coated coverslips to 50-60% confluency 
24 hrs prior to use and incubated under normal cell conditions.  For each plasmid to be 
transfected, the following mix was prepared per well in the order listed:  97 ul DMEM (-) 
(Dulbecco's Modified Eagle Media, warmed to 37ºC), 4 ul FUGENE 6 (placed at room 
temperature 15 minutes prior to preparation and vortexed), and 0.4-0.8 ug plasmid DNA.  
This sample was mixed and allowed to incubate at least 20 min at room temperature.  The 
plated cells were then washed with 500 ul DMEM (-) per well and 500 ul fresh DMEM  
(-) was added.  Each prepared mix was then added to wells, the plate was swirled, and 
then placed back into the incubator.  After 6 hours, the media was changed from DMEM 
(-) to DMEM (+) (DMEM + 10% FBS and 5 mL Pen-Strep).  The transfection mixture 
was then incubated overnight.  The cells were fixed on glass slides 24 hours post initial 
transfection.  Plates were placed on ice and covered from light.  Cells were washed three 
times with 500 ul PBS per well, 5 minutes each wash, and covered in between washes.  
Cells were then incubated 10 minutes covered on ice with 500 ul per well PFA.  Cells 
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were washed again three times with 500 ul PBS per well, 5 minutes each.  After all 
washes, coverslips were drained and fixed on glass slides with dapi-vectashield and glue.  
Finally, localization of the EGFP-L2 fusion proteins was analyzed via fluorescence 
microscopy.   
 
Results  
EGFP-16L2 is localized in the nucleus in vivo.   
 An EGFP reporter protein was used to investigate the localization of HPV16 L2 
in vivo by constructing a recombinant EGFP-16L2 plasmid to be used in transfection 
assay.  HeLa cells were transfected with the EGFP-16L2 plasmid and subcellular 
localization was visualized 24h post transfection.  Transfection with the EGFP plasmid 
serves as the control, as EGFP is capable of passive diffusion through the nuclear pore 
complex and therefore localizes diffusely throughout the cell (Figure 3, panel B) when 
compared with nuclear DAPI staining (Figure 3, panel A).  The wild-type HPV16 L2 
localizes to the nucleus (Figure 3, panel D), as made clear in comparison to the 
visualization of the nucleus with the DAPI staining (Figure 3, Panel C).  Quantitation of 
80 HeLa cells shows EGFP-16L2 to localize in the nucleus in 55% of cells, with 45% of 
cells showing diffuse localization throughout the cell (Table 2).  Graphic representation 
of the quantitative analysis of subcellular localization is shown (Figure 6).   
 
The nNLS of HPV16 L2 can mediate nuclear localization of HPV16 L2 in vivo. 
 An EGFP reporter protein was used to investigate the role of the nNLS of HPV16 
L2 in vivo by constructing recombinant EGFP-L2, EGFP-L2∆C and EGFP-L2∆N∆C 
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plasmids.  HeLa cells were transfected with the plasmids and subcellular localization was 
visualized 24h post transfection.  EGFP-16L2∆C clearly localizes to the nucleus (Figure 
4, Panel D), shown in correlation with the visualization of the nuclei with DAPI staining 
(Figure 4, Panel C).  Quantitation has shown that approximately 98% of cells exhibit 
nuclear localization when transfected with the EGFP-16L2∆C mutant (Table 2).  The 
nuclear localization by the nNLS alone is comparable to that of the full length EGFP-
16L2 (Figure 4, panel B).  With the deletion of both the nNLS and cNLS in the EGFP-
L2∆N∆C mutant, however, nuclear localization was abolished (Figure 4, Panel H), 
resulting in mostly cytoplasmic localization of the protein.  Quantitation studies have 
shown that while approximately 31% of cells retain nuclear localization of L2∆N∆C, 
56% show localization throughout the cell and about 12.5% show mostly cytoplasmic 
localization (Table 2).  DAPI nuclear staining is also shown (Figure 4, panels A and G).  
Thus, the nNLS is capable of mediating nuclear localization of HPV16 L2 and deletion of 
both the nNLS and cNLS results in clear loss of nuclear localization.  Quantitative 
analysis of subcellular localization of HPV16 L2 and L2 mutants has been represented 
graphically (Figure 6).   
 
Mutation of basic residues in the nNLS of HPV16 L2 inhibits its nuclear import 
ability. 
A mutant EGFP-16L2∆CsbN plasmid was created in which the wild-type 
sequence of the nNLS, MRHKRSAKRTKR, was changed to MRHKRSAAATKR (Table 
1).  The basic residues arginine and lysine were therefore changed to two neutral alanine 
residues.  The EGFP reporter protein was used to investigate the nuclear import ability of 
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the mutated nNLS of HPV16 L2 in vivo by transfecting HeLa cells with the recombinant 
plasmid and visualizing subcellular localization 24h post transfection.  The nuclei have 
been visualized using DAPI staining (Figure 4`, panels A, C, E and G).  Compared to the 
strong nuclear localization of both EGFP-16L2 (Figure 4`, panel B) and EGFP-16L2∆C 
(Figure 4`, panel D), the nuclear localization of EGFP-16L2∆CsbN was largely disrupted 
(Figure 4`, panel F).  The level of EGFP-16L2∆CsbN protein remaining in the cytoplasm 
more closely resembles that of the EGFP-16L2∆N∆C double mutant (Figure 4`, panel H).  
As such, the mutation of basic residues in the nNLS resulted in a complex phenotype.  
While nuclear localization still occurs in approximately 51% of cells (Table 2), this 
localization is much less defined, with more protein localized to the cytoplasm than seen 
with the EGFP-16L2∆C mutant.  Further, a substantial 36% of cells showed localization 
throughout the cell and about 13% were mostly cytoplasmic in the localization of the 
protein (Table 2).  Thus, it has been shown that the mutation of basic residues in the 
nNLS of HPV16 L2 inhibits its nuclear import ability.  Quantitative analysis of 
subcellular localization has been visualized graphically (Figure 6).   
 
The cNLS of HPV16 L2 can mediate nuclear localization of HPV16 L2 in vivo. 
 An EGFP reporter protein was used to investigate the role of the cNLS of HPV16 
L2 in vivo by constructing recombinant EGFP-L2, EGFP-L2∆N and EGFP-L2∆N∆C 
plasmids.  HeLa cells were transfected with the plasmids and subcellular localization was 
visualized 24h post transfection.  EGFP-16L2∆N shows strong nuclear localization 
(Figure 5, Panel D), with 98% of cells showing nuclear localization in quantitative 
analysis (Table 2).  As compared to nuclear visualization through DAPI staining (Figure 
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5, panels A and C), the single deletion mutant EGFP-16L2∆N shows nuclear localization 
similar to that of the full length EGFP-16L2 (Figure 5, panel B).  The EGFP-L2∆N∆C 
mutant, having deleted both the nNLS and cNLS, lost this strong nuclear localization 
(Figure 5, Panel H).  DAPI nuclear staining for the double mutant is also shown (Figure 
5, panel G).  The data suggests that the cNLS is capable of independently mediating 
nuclear localization of HPV16 L2.  Graphic representation of the quantitative analysis of 
subcellular localization is shown (Figure 6).   
 
Mutation of basic residues in the cNLS of HPV16 L2 inhibits its nuclear import 
ability. 
The wild-type sequence of the cNLS of HPV16 L2, RKRRKR, contains basic 
residues implicated in its function as a classical NLS.  A mutant EGFP-16L2∆NsbC 
plasmid was created in which the cNLS sequence was changed to RKEEKR (Table 1), 
exchanging arginine and lysine for two glutamic acid residues.  The EGFP reporter 
protein was used to investigate the nuclear import ability of the mutated cNLS of HPV16 
L2 in vivo by transfecting HeLa cells with the recombinant plasmid and visualizing 
subcellular localization 24h post transfection.  The nuclei have been visualized using 
DAPI staining (Figure 5`, panels A, C, E, and G).  As opposed to the very clear nuclear 
localization seen for EGFP-16L2∆N (Figure 5`, panel D), a far greater amount of the 
EGFP-16L2∆NsbC mutant is localized to the cytoplasm (Figure 5`, panel F).  
Quantitative analysis has shown a retention of nuclear localization in approximately 77% 
of cells.  However, the EGFP-16L2∆NsbC mutant nuclear localization was generally 
accompanied by higher levels of protein in the cytoplasm than those with only a single 
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deletion of the nNLS.  Approximately 16% of cells transfected with this mutant showed 
localization throughout the cell, and about 1.3% showed mostly cytoplasmic localization 
(Table 2). The data reveals a complex phenotype, yet shows some inhibition in the ability 
of the cNLS to mediate nuclear import with the mutation of basic residues.  Quantitative 
analysis of subcellular localization of HPV16 L2 and mutants has been represented 
graphically (Figure 6).   
 
The nNLS and cNLS of HPV11 L2 can independently mediate nuclear localization 
of HPV11 L2. 
An EGFP reporter protein was used to investigate the role the nNLS and cNLS of 
HPV11 L2 in vivo by constructing recombinant EGFP-11L2, EGFP-L2∆N, EGFP-L2∆C, 
and EGFP-L2∆N∆C plasmids, transfecting HeLa cells and visualizing subcellular 
localization 24h post transfection.  The wild-type EGFP-11L2 clearly localizes to the 
nucleus (Fig. 7A, panel A) when compared to the localization of EGFP throughout the 
cell (Fig. 7A, panel C).  The nuclei were also visualized with DAPI staining (Fig. 7A, 
panels B and D).  Both the EGFP-L2∆N (Fig. 7B, panel A) and the EGFP-L2∆C (Fig. 
7B, panel C) proteins also localize primarily to the nucleus, however not as efficiently as 
the wild-type EGFP-L2, as some of the protein was still located in the cytoplasm for each 
single mutant when compared with the nuclear DAPI staining (Fig. 7B, panels B and D). 
With the EGFP-L2∆N∆C double deletion mutant (Fig. 7B, panel E) nuclear localization 
was no longer seen and the majority of the protein was cytoplasmic when compared to 
the nuclear DAPI staining (Fig. 7B, panel F).  Graphic representation of the quantitative 
analysis of subcellular localization is shown (Figure 10).                                         
*Figure and results taken from Jennifer Bordeaux (Bordeaux et al., 2006).   
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Mutation of basic residues in the nNLS of HPV11 L2 inhibits its nuclear import 
ability. 
A mutant EGFP-H11L2∆CsbN plasmid was created in which the wild-type 
sequence of the nNLS, MKPRARRRKRA, was changed to MKPRARAAKRA (Table 1).  
The basic residues arginine and lysine were thus changed to two neutral alanine residues.  
The EGFP reporter protein was used to investigate the nuclear import ability of the 
mutated nNLS of HPV11 L2 in vivo by transfecting HeLa cells with the recombinant 
plasmid and visualizing subcellular localization 24h post transfection.  The nuclei have 
been visualized using DAPI staining (Figure 8, panels A, C, E, and G; Figure 8`, panels 
A, C, E, and G).  Compared to the strong nuclear localization of both EGFP-11L2 (Figure 
8, panel B; Figure 8`, panel B) and EGFP-11L2∆C (Figure 8, panel D; Figure 8`, panel 
D), the nuclear localization of EGFP-11L2∆CsbN was abolished (Figure 8, panel F; 
Figure 8`, panel F).  Quantitative analysis revealed that only 28% of cells retained nuclear 
localization when transfected with the EGFP-11L2∆CsbN plasmid (Table 2).  Rather, 
about 43.5% of cells showed the protein to be localized throughout the cell while a 
considerable 28.5% of cells showed the protein to be localized cytoplasmically (Table 2).  
The resultant phenotypes have shown that mutation of basic residues in the nNLS of 
HPV11 L2 clearly inhibits its nuclear import ability.  Graphic representation of the 
quantitative analysis of subcellular localization of HPV11 L2 is shown (Figure 10).   
Mutation of basic residues in the cNLS of HPV11 L2 inhibits its nuclear import 
ability. 
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A mutant EGFP-16L2∆NsbC plasmid was created in which the wild-type cNLS 
sequence was changed from RRRRKR to RRAAKR (Table 1), exchanging arginine and 
lysine for two neutral alanine residues.  The EGFP reporter protein was used to 
investigate the nuclear import ability of the mutated cNLS of HPV16 L2 in vivo by 
transfecting HeLa cells with the recombinant plasmid and visualizing subcellular 
localization 24h post transfection.  The nuclei have been visualized using DAPI staining 
(Figure 9, panels A, C, E, and G; Figure 9`, panels A, C, E, and G).  While very clear 
punctate nuclear localization is seen for HPV11 L2 (Figure 9, panel B; Figure 9`, panel 
B) and EGFP-11L2∆N (Figure 9, panel D; Figure 9`, panel D), cells expressing the 
EGFP-11L2∆NsbC mutant clearly show a disruption in nuclear import (Figure 9, panel F; 
Figure 9`, panel F), although multiple phenotypes do occur.  Quantitative analysis shows 
only 32% of cells transfected with the EGFP-11L2∆NsbC plasmid to exhibit nuclear 
localization (Table 3).  Further, 28.5% of cells had localization throughout the cell and 
about 39% showed cytoplasmic localization (Table 3).  The data has shown that the 
mutation of basic residues in the cNLS of HPV11 L2 disrupts the ability to mediate 
nuclear import.  Graphic representation of the quantitative analysis of subcellular 







 The L2 minor capsid protein of high-risk HPV16 and low-risk HPV11 contains 
two nuclear localization signals, the nNLS and the cNLS, which mediate nuclear import 
of the protein.  Previous in vitro assays have identified the capacity of the NLSs to bind 
both to specific nuclear import adaptors and receptors and to nonspecific DNA (Darshan 
et al., 2004; Bordeaux et al., 2006).  Novel in vivo nuclear localization studies on HPV16 
L2 have been conducted in this research, as well as in vivo investigations on the effect 
which specific NLS mutations have on the nuclear localization of HPV16 L2 and HPV11 
L2.  
The full-length HPV16 L2 protein was shown to localize to the nucleus.  Though 
quantitation showed nuclear localization in only 55% of cells, it is important to note that 
0% of cells had mostly cytoplasmic localization of the protein.  Overexpression of the 
protein has been proposed to account for the excess of the L2 minor capsid protein 
remaining in the cytoplasm in the resultant 45% of cells with diffuse localization.  
Without overexpression, HPV16 L2 would be expected to localize to the nucleus in the 
majority of cells, similar to the subcellular localization of HPV16 L2∆N and L2∆C 
mutants.   
Given the nuclear localization of HPV16 L2, the capacity of each NLS to 
independently mediate nuclear import was studied.  It was shown that the deletion of a 
single NLS, either the nNLS or the cNLS, still resulted in efficient nuclear localization of 
the protein.  Deletion of both NLSs, however, significantly disrupted nuclear localization.  
The retention of some nuclear localization in cells expressing the HPV16 L2∆N∆C 
double mutant suggests the possibility of a third moderately functioning NLS.  An mNLS 
in HPV16 L2 has previously been studied and found nonfunctional in vitro.  However, 
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the mNLS may be playing a role in nuclear retention in vivo as previously suggested 
(Darshan et al., 2004).  Thus, it has been shown that both the nNLS and the cNLS are 
capable of independently mediating nuclear import.    
Previous research has shown that HPV11 L2 localizes to the nucleus in vivo.  This 
investigation also revealed that the nNLS and cNLS of HPV11 L2 can independently 
mediate nuclear import.  Further, deletion of both the nNLS and the cNLS abolishes 
nuclear localization (Bordeaux et al., 2006).  Quantitation of transfection assays using the 
same HPV11 L2 full-length and mutant plasmids has supported these findings. 
As both HPV16 L2 and HPV11 L2 have been shown to contain NLSs capable of 
independently mediating nuclear import, further investigation seeks to identify the 
minimal mutation necessary to abolish the nuclear import ability of a given NLS.  As 
classical NLSs are defined by their composition of basic amino acids, HPV16 and 11 L2 
proteins with NLS mutations to either neutral or acidic residues were analyzed for 
nuclear localization in vivo.  A complex phenotype was revealed in the mutation-function 
analysis of subcellular localization for each mutant.  The substitution in the nNLS of 
HPV16 L2 proved to be more effective at inhibiting nuclear localization than the 
substitution in the cNLS.  While cells transfected with the HPV16 L2∆CSbN and 
L2∆NSbC mutants showed all three phenotypes of nuclear, diffuse, and cytoplasmic 
localization, the NLS mutations undoubtedly disrupted nuclear import.  The HPV11 
L2∆CSbN and L2∆NSbC mutants were shown to be more effective in their inhibition of 
nuclear import.  Both mutants substituted a neutral amino acid for a basic amino acid, and 
inhibited nuclear localization to a similar degree.  Cells expressing the HPV11 L2∆NSbC 
protein showed a higher rate of mostly cytoplasmic localization.  Further mutation-
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function analysis of new L2 mutants may reveal mutations with even higher efficiency at 
preventing nuclear localization.   
Having shown that mutation of basic residues in the NLSs of HPV16 L2 and 
HPV11 L2 inhibits nuclear import ability, further study of these L2 mutants will help to 
elucidate the role of the L2 minor capsid protein in the HPV life cycle.  The punctate 
pattern of L2 localization within the nucleus previously reported was also seen in this 
study for both types HPV16 and 11.  Investigation of these L2 mutants in association 
with the nuclear domains 10 may also be made in the future (Day et al., 1998).    
Immunoblot assays will be necessary to ensure the proteins expressed are not degraded in 
the transfections with L2 plasmids.  In vitro import assays of the HPV16 and 11 L2 
substitution mutants will also be necessary to substantiate in vivo findings.  Further 
investigation in vivo into the possible mNLS of HPV16 L2 may also be made in the 
future.  As the minimal mutation necessary to abolish the nuclear import ability of the 
HPV16 and 11 L2 NLSs is clarified, these L2 mutants may be used to further understand 
the functions of the L2 minor capsid protein and to potentially disrupt its role in the 












Illustration of the HPV16 genome.  The image illustrates the open reading frames for 
the early genes (E1, E2, E4, E5, E6, and E7) and the late genes (L1 and L2).  The 
proteins are conserved between high-risk and low-risk strains. 














Model for nuclear import of classic NLS-containing proteins.  Low levels of RanGTP 
in the cytoplasm allow for the stable formation of a trimeric complex consisting of the 
NLS-protein cargo and the Kap αβ1 heterodimer.  The complex is translocated through 
the nuclear pore complex and high levels of RanGTP in the nucleus dissociate the Kap 
αβ1 complex, releasing the NLS-protein cargo. Kap α and Kap β1/Ran GTP are then 
exported via separate pathways back into the cytoplasm.  (Moroianu, J., Nuclear import 



































NLSs and mutated NLSs of HPV16/11 L2 proteins.  In order to disrupt the nuclear 
import ability of the classical nuclear localization signals of HPV16 L2 and HPV11 L2 
proteins, basic residues were changed to neutral or acidic residues in either the nNLS or 





















NLSs and mutated NLSs of HPV16/11 L2 proteins 
 
HPV16 L2 nNLS:  MRHKRSAKRTKR 
HPV16 L2 nNLS mut: MRHKRSAAATKR 
HPV16 L2 cNLS:  RKRRKR 
HPV16 L2 cNLS mut: RKEEKR 
 
HPV11 L2 nNLS:  MKPRARRRKRA 
HPV11 L2 nNLS mut: MKPRARAAKRA 
HPV11 L2 cNLS:  RRRRKR 
HPV11 L2 cNLS mut: RRAAKR 
 
K:  Lysine (basic) 
R:  Arginine (basic) 
A:  Alanine (neutral) 






Figure 3.   
EGFP-16L2 is localized in the nucleus in vivo. HeLa cells were transfected with either 
EGFP (panels A and B) or EGFP-L2 (panels C and D) plasmids, using FUGENE 6, and 
were examined by fluorescence microscopy at 24 h post transfection. The DAPI (4’, 6’-
diamidino-2-phenylindole) staining of the nuclei is shown in the left column and the 
























Figure 4.   
The nNLS of HPV16 L2 can mediate nuclear localization of HPV16 L2 in vivo. HeLa 
cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆C (panels C and 
D), EGFP-L2∆CsbN (panels E and F), or EGFP-L2∆N∆C (panels G and H) plasmids, 
using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection.  The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 







Mutation of basic residues in the nNLS of HPV16 L2 inhibits its nuclear import 
ability. HeLa cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆C 
(panels C and D), EGFP-L2∆CsbN (panels E and F), or EGFP-L2∆N∆C (panels G and 
H) plasmids, using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection.  The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 






Figure 5.  
The cNLS of HPV16 L2 can mediate nuclear localization of HPV16 L2 in vivo. HeLa 
cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆N (panels C and 
D), EGFP-L2∆NsbC (panels E and F), or EGFP-L2∆N∆C (panels G and H) plasmids, 
using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection. The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 
shown in the left column and the fluorescence of the EGFP is shown in the right column.   





Mutation of basic residues in the cNLS of HPV16 L2 inhibits its nuclear import 
ability. HeLa cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆N 
(panels C and D), EGFP-L2∆NsbC (panels E and F), or EGFP-L2∆N∆C (panels G and 
H) plasmids, using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection. The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 















          
16L2 55.00 ± 25.17 45.00 ± 25.17 0 80 
          
16L2∆C 98.33 ±  2.89  0.33 ±  0.33 0 44 
     
16L2∆CsbN 50.79 ± 19.23 36.51 ±  26.23 12.70 ±  14.55 51 
     
16L2∆N 98.41 ±  2.75  0.33 ± 0.58 0 61 
          
16L2∆NsbC 77.22 ±  11.82  16.27 ±  6.99 1.33 ±  1.15 61 
          




Quantitation of subcellular localization of HPV16 L2 and mutants.  Localization of 
HPV16 L2 full length and mutant proteins was quantitated in multiple transfection 








































Figure 6.   
Subcellular localization of HPV16 L2 minor capsid protein and mutants.  

























The nNLs and cNLS of HPV11 L2 can independently mediate nuclear localization 
of HPV11 L2. HeLa cells were transfected with either EGFP (A, panels A and B), 
EGFP-L2 (A, panels C and D), EGFP-L2∆N (B, panels A and B), EGFP-L2∆C (B, 
panels C and D), or EGFP-L2∆N∆C (B, panels E and F) plasmids, using FUGENE 6, and 
were examined by fluorescence microscopy at 24 h posttransfection.  The DAPI (4’, 6’-
diamidino-2-phenylindole) staining of the nuclei is shown in the left column and the 




Figure 8.  
Mutation of basic residues in the nNLS of HPV11 L2 inhibits its nuclear import 
ability. HeLa cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆C 
(panels C and D), EGFP-L2∆CsbN (panels E and F), or EGFP-L2∆N∆C (panels G and 
H) plasmids, using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection.  The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 






Mutation of basic residues in the nNLS of HPV11 L2 inhibits its nuclear import 
ability. HeLa cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆C 
(panels C and D), EGFP-L2∆CsbN (panels E and F), or EGFP-L2∆N∆C (panels G and 
H) plasmids, using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection.  The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 






Mutation of basic residues in the cNLS of HPV11 L2 inhibits its nuclear import 
ability. HeLa cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆N 
(panels C and D), EGFP-L2∆NsbC (panels E and F), or EGFP-L2∆N∆C (panels G and 
H) plasmids, using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection.  The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 









Mutation of basic residues in the cNLS of HPV11 L2 inhibits its nuclear import 
ability. HeLa cells were transfected with either EGFP-L2 (panels A and B), EGFP-L2∆N 
(panels C and D), EGFP-L2∆NsbC (panels E and F), or EGFP-L2∆N∆C (panels G and 
H) plasmids, using FUGENE 6, and were examined by fluorescence microscopy at 24 h 
posttransfection.  The DAPI (4’, 6’-diamidino-2-phenylindole) staining of the nuclei is 
















          
11L2 96.37 ± 3.17 3.63 ± 3.17 0 57 
          
11L2∆C 100.00 ±  0.00 0 0 50 
          
11L2∆CsbN 28.00 ± 11.31 43.50 ±  12.02 28.5 ±  23.33 45 
     
11L2∆N 100.00 ±  0.00  0 0 62 
     
11L2∆NsbC 32.15 ±  13.99   28.51 ±  15.45 39.32 ±  21.54 76 
          




Quantitation of subcellular localization of HPV11 L2 and mutants.  Localization of 
HPV11 L2 full length and mutant proteins was quantitated in multiple transfection 















































Figure 10.   
Subcellular localization of HPV11 L2 minor capsid protein and mutants.  
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